$40.15
0.55%
Nasdaq, Nov 17, 04:00 pm EST. Closed.
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Stock price

$40.15
-9.89 19.76% 1M
-8.41 17.32% 6M
-12.29 23.44% YTD
-15.17 27.42% 1Y
-27.74 40.86% 3Y
-45.93 53.36% 5Y
+18.35 84.17% 10Y
+26.06 184.95% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.22 0.55%
ISIN
CH0334081137
Symbol
CRSP
Industry

AI Insights on CRISPR Therapeutics AG Insights AI Insights on CRISPR Therapeutics AG

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is CRISPR Therapeutics AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$2.2b
Net debt
positive
Cash
$2.3b
Shares outstanding
96.9m
Valuation
P/E
negative
P/S | estimate
155.6 | 122.2
EV/Sales | estimate
88.6 | 69.6
EV/FCF | ex SBC
negative | negative
P/B
2.4
Financial Health
Equity Ratio
84.8%
Return on Equity
-30.3%
ROCE
-21.5%
ROIC
-213.9%
Debt/Equity
0.4
Share-Based Compensation & Dilution
SBC | % of Revenue
$69.7m | 276.8%
SBC as % of FCF
-
SBC Growth 1Y
-8.8%
Share Count Growth 1Y
3.2%
Shareholder Yield
-3.2%
Financials
Revenue | estimate
$25.2m | $32.0m
EBITDA
$-499.7m
EBIT
$-518.2m
Net Income
$-456.1m
Free Cash Flow | ex SBC
$-378.4m | $-448.0m
Growth
Revenue | estimate
-34.4% | 812.8%
EBITDA
-8.7%
EBIT
-8.4%
Net Income
6.6%
Free Cash Flow
-15.3%
Margin
Gross
-
EBITDA
-1,985.1%
EBIT
-2,058.6%
Net
-1,812.1%
Free Cash Flow | ex SBC
-1,503.1% | -1,779.9%
More
EPS
$-4.7
FCF per Share
$-3.9
Short interest
20.3%
Employees
393
Rev per Employee
$10.0k

CRISPR Therapeutics AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a CRISPR Therapeutics AG forecast:

17x Buy
59%
12x Hold
41%

Analyst Opinions

29 Analysts have issued a CRISPR Therapeutics AG forecast:

Buy
59%
Hold
41%

CRISPR Therapeutics AG Events

Past Events
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
JUN
3
46th Annual William Blair Growth Stock Conference
6 months ago
JUN
3
Jefferies Global Healthcare Conference 2026
6 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
APR
13
25th Annual Needham Virtual Healthcare Conference
7 months ago
FEB
18
Citi’s 2026 Virtual Oncology Leadership Summit
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago

Financial data from CRISPR Therapeutics AG

Sep '26
+/-
%
25 25
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 252 252
8% 8%
1,002%
- Research and Development Expense 291 291
3% 3%
1,157%
-500 -500
9% 9%
-1,985%
- Depreciation and Amortization 19 19
1% 1%
74%
EBIT (Operating Income) EBIT -518 -518
8% 8%
-2,059%
Net Profit -456 -456
7% 7%
-1,812%

In millions USD.

Don't miss a Thing! We will send you all news about CRISPR Therapeutics AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CRISPR Therapeutics AG Stock News

Neutral
GlobeNewsWire
●
8 days ago
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level above 1,000 mg/dL- -CTX310 was well tolerated, with no treatment-related serious adverse events and...
Neutral
GlobeNewsWire
●
9 days ago
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
Neutral
GlobeNewsWire
●
15 days ago
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older – – FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX...
More CRISPR Therapeutics AG News

Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Dr. Kulkarni
Employees 393
Founded 2013
Website crisprtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today